Breast Biopsy Devices Sales

Breast Biopsy Devices Sales Market Outlook

The global breast biopsy devices market is projected to reach approximately USD 2.5 billion by 2035, growing at a compound annual growth rate (CAGR) of around 7% from 2025 to 2035. This steady growth is primarily driven by the escalating prevalence of breast cancer across various demographics, leading to an increased demand for early diagnosis and effective treatment options. Additionally, advancements in biopsy technologies and rising awareness regarding breast health among women are contributing significantly to market growth. The integration of minimally invasive procedures and improved patient comfort has also fueled the adoption of these devices. Furthermore, the growing investment in healthcare infrastructure and research is expected to provide a favorable environment for market expansion.

Growth Factor of the Market

One of the most significant growth factors influencing the breast biopsy devices market is the increasing incidence of breast cancer worldwide. With the World Health Organization estimating that breast cancer is the most common cancer among women, the demand for effective diagnostic solutions is on the rise. Moreover, the trend toward early detection is reshaping patient management and treatment protocols, leading to a greater utilization of breast biopsy devices. Technological advancements, such as the introduction of robotic-assisted biopsy systems and enhanced imaging techniques, have improved the accuracy and safety of breast biopsies. In addition, the rise in health awareness campaigns and initiatives aimed at educating women about the importance of regular screenings and early diagnosis has further propelled market growth. Additionally, the expansion of healthcare facilities and the increasing availability of specialized clinics also contribute to the overall market landscape, creating a conducive environment for breast biopsy device sales.

Key Highlights of the Market

• Projected growth of the breast biopsy devices market at a CAGR of 7% from 2025 to 2035.
• Increased focus on early detection and diagnosis of breast cancer globally.
• Technological innovations leading to enhanced accuracy and patient comfort.
• Growing investment in healthcare infrastructure and diagnostic capabilities.
• Rise in awareness regarding breast health among women, promoting regular screenings.

By Product Type

Core Needle Biopsy Devices

Core needle biopsy devices are becoming increasingly popular owing to their efficacy in providing accurate tissue samples for diagnostic purposes. This method is less invasive than surgical biopsy and allows for quicker recovery times for patients. These devices utilize a hollow needle to remove several small cylinders of tissue from the breast, which are then examined for any anomalies or cancerous cells. The accuracy and reliability of core needle biopsies have made them a preferred choice among healthcare providers, contributing to their significant market share. Furthermore, these devices are increasingly being integrated with imaging technologies such as ultrasound and MRI to enhance localization and precision. The growing preference for minimally invasive procedures is also driving up demand in this segment, making core needle biopsy devices a critical component of the breast biopsy devices market.

Vacuum-assisted Biopsy Devices

Vacuum-assisted biopsy devices represent another key segment within the breast biopsy devices market, known for their ability to extract larger tissue samples in a single procedure. This method utilizes a vacuum mechanism to collect multiple samples through a single incision, significantly reducing the number of biopsies required. Vacuum-assisted biopsies are often preferred in cases where a more comprehensive analysis is needed or when there are suspicious lesions that require further investigation. The growing body of evidence supporting the efficiency and effectiveness of vacuum-assisted biopsy techniques has led to their widespread adoption in both hospital and outpatient settings. As healthcare professionals increasingly recognize the benefits of this approach, the segment continues to expand, bolstered by advancements in device technology that enhance both safety and patient comfort.

Fine Needle Aspiration Biopsy Devices

Fine needle aspiration biopsy (FNAB) devices are instrumental in the early detection and diagnosis of breast abnormalities. This technique involves using a thin needle to extract a small amount of tissue or fluid for cytological evaluation, making it a less invasive option for patients. FNAB is particularly useful in cases where the lesion is palpable, allowing for quick and effective diagnostic procedures. The low complication rates associated with FNAB, coupled with its cost-effectiveness, have significantly contributed to its popularity within the healthcare community. Furthermore, the increasing emphasis on patient-centered care and the demand for rapid diagnostic solutions have further solidified the position of fine needle aspiration biopsy devices within the market. The ongoing development of more refined and user-friendly devices continues to drive growth in this segment.

MRI-guided Biopsy Devices

MRI-guided biopsy devices have emerged as a crucial advancement in breast biopsy technology, particularly for patients with dense breast tissue where traditional imaging may not be as effective. This method utilizes magnetic resonance imaging to precisely locate and target lesions, ensuring accurate sample extraction. The ability to visualize soft tissue abnormalities makes MRI-guided biopsies invaluable for diagnosing breast cancer at earlier stages. The increased adoption of MRI-guided biopsy devices is supported by the growing availability of MRI facilities in hospitals and outpatient settings. As more healthcare providers integrate advanced imaging techniques into their diagnostic protocols, the demand for MRI-guided biopsy devices is expected to rise, further enhancing their market presence.

Ultrasound-guided Biopsy Devices

Ultrasound-guided biopsy devices are widely recognized for their effectiveness in targeting breast lesions that are difficult to identify through palpation alone. By using real-time imaging, these devices allow clinicians to accurately navigate to the site of interest, thus improving the precision of the biopsy procedure. The increasing preference for ultrasound guidance is driven by its non-invasive nature, ease of use, and absence of ionizing radiation. Additionally, the rising incidence of breast cancer has increased the focus on non-invasive diagnostic techniques, further propelling the demand for ultrasound-guided biopsy devices. As technology continues to evolve, advancements in ultrasound imaging and device design are expected to enhance the efficacy of these biopsies, ensuring their continued relevance in breast cancer diagnostics.

By Application

Hospitals

Hospitals remain the primary setting for breast biopsy procedures, accounting for a significant share of the application segment in the breast biopsy devices market. The comprehensive care offered in hospitals, including surgical, diagnostic, and follow-up services, makes them a preferred choice for patients undergoing breast biopsies. With access to advanced imaging modalities and trained healthcare professionals, hospitals can facilitate a seamless biopsy process. The increasing investment in hospital infrastructure and the adoption of state-of-the-art technologies further enhance the capabilities of these facilities. As the prevalence of breast cancer rises, hospitals are likely to see an uptick in the volume of biopsy procedures performed, driving growth in this application segment.

Diagnostic Centers

Diagnostic centers play a pivotal role in the breast biopsy devices market, offering specialized services that cater to patients seeking quick and reliable diagnostic results. These centers typically focus on imaging and outpatient procedures, allowing for a more streamlined approach to breast health assessments. The convenience offered by diagnostic centers, combined with reduced wait times for procedures and results, has led to a growing preference among patients. Advances in imaging technologies and minimally invasive techniques are further propelling the use of biopsy devices within these centers. As healthcare becomes increasingly patient-centric, diagnostic centers are expected to capture a larger share of the market, making them a critical component of the overall breast biopsy landscape.

Ambulatory Surgical Centers

Ambulatory surgical centers (ASCs) are gaining traction as a viable option for breast biopsy procedures, offering patients an alternative to traditional hospital settings. These facilities provide a cost-effective solution for outpatient surgical procedures, allowing patients to undergo biopsies in a comfortable and efficient environment. The increasing shift toward outpatient care is fueled by the desire for convenience and lower healthcare costs. ASCs also reduce the burden on hospitals, allowing them to focus on more complex cases. The rise in the number of ASCs and their emphasis on high-quality, timely care is expected to contribute positively to the breast biopsy devices market, further diversifying the options available to patients.

Others

This category encompasses various other applications of breast biopsy devices, including those utilized in research institutions, cancer screening programs, and women’s health initiatives. The versatility of breast biopsy devices in various settings highlights their importance in a broader healthcare context. Research institutions utilize these devices for clinical studies aimed at understanding breast cancer progression and treatment outcomes, facilitating advancements in the field. Additionally, community health programs that focus on breast health education and screening are increasingly adopting biopsy devices to enhance their diagnostic capabilities. The multifaceted applications of breast biopsy devices in diverse settings contribute to their overall market growth, allowing for expanded reach and utilization.

By End User

Women's Health Clinics

Women’s health clinics are crucial end-users of breast biopsy devices, providing specialized care and services tailored to women's health needs. These clinics often focus on preventative care and early detection of breast cancer, making them a vital component of the diagnostic process. The personalized approach taken by these clinics fosters a supportive environment for women undergoing biopsies. As awareness regarding breast health continues to rise, women’s health clinics are witnessing an increase in patient volume and biopsy procedures. These clinics are also at the forefront of implementing new technologies, including advanced biopsy devices that prioritize patient comfort and diagnostic precision. Consequently, the growth of women’s health clinics is closely tied to the expansion of the breast biopsy devices market.

Cancer Research Institutes

Cancer research institutes serve as significant end-users of breast biopsy devices, utilizing them for both diagnostic and research purposes. These institutes focus on understanding the complexities of breast cancer, exploring novel treatments, and improving diagnostic techniques. By employing various biopsy methods, researchers can gather critical data that informs their studies and ultimately contributes to advancements in cancer care. The collaboration between research institutes and healthcare providers enhances the overall knowledge base regarding breast cancer, supporting the development of innovative therapies and diagnostic tools. As research efforts intensify and funding for cancer research continues to grow, the demand for breast biopsy devices within these institutes is anticipated to rise, further driving the market forward.

Others

This segment encompasses a range of other end-users, including educational institutions, public health organizations, and other entities involved in breast health initiatives. Educational institutions often utilize breast biopsy devices for training and research purposes, ensuring that future healthcare professionals are well-versed in the latest diagnostic techniques. Public health organizations employ these devices in screening programs aimed at reducing breast cancer morbidity and mortality rates. The diverse applications of breast biopsy devices across various end-users highlight their importance in addressing the broader public health challenge of breast cancer. As efforts to improve breast cancer screening and treatment evolve, the utilization of biopsy devices in these additional settings will continue to foster market growth.

By Modality

MRI-guided Biopsy

MRI-guided biopsies represent a sophisticated modality that leverages advanced imaging technology to enhance the accuracy of breast cancer diagnosis. This method is particularly beneficial for lesions that are not easily visible on traditional mammograms or ultrasound. By utilizing MRI, healthcare providers can obtain detailed images that guide them in precisely targeting the area of interest during the biopsy procedure. The effectiveness of MRI-guided biopsies in detecting and diagnosing breast cancer abnormalities has made them increasingly popular among clinicians. As technology advances and becomes more accessible in various healthcare settings, the adoption of MRI-guided biopsy devices is expected to continue growing, bolstering their share in the breast biopsy devices market.

Stereotactic-guided Biopsy

Stereotactic-guided biopsy is a technique that integrates imaging guidance to enable accurate localization of breast lesions. This method typically employs mammography to pinpoint the exact location of the abnormality before the biopsy procedure begins. The precision offered by stereotactic guidance significantly enhances the chances of obtaining an adequate tissue sample for analysis, thereby improving diagnostic outcomes. As healthcare providers increasingly adopt this technique, the demand for stereotactic-guided biopsy devices is expected to rise. The benefits of this modality, including its minimally invasive nature and reduced recovery times, contribute to its growing popularity among patients and healthcare practitioners alike.

Ultrasound-guided Biopsy

Ultrasound-guided biopsy is widely recognized for its effectiveness in targeting breast lesions that may not be easily palpable. Utilizing real-time imaging, this modality allows healthcare professionals to visualize the lesion during the biopsy procedure, ensuring accurate sample collection. The non-invasive nature of ultrasound-guided biopsies, along with the absence of ionizing radiation, makes it an attractive option for both clinicians and patients. The increasing adoption of this technique is fueled by its ability to provide rapid results and enhance patient comfort. As advancements in ultrasound technology continue to emerge, the relevance of ultrasound-guided biopsy devices within the breast biopsy market is expected to strengthen.

Others

This category includes various other modalities used in breast biopsy procedures, such as computer-assisted and robotic-assisted technologies. These advanced modalities are designed to improve precision, reduce procedural time, and enhance the overall patient experience. Computer-assisted biopsy systems leverage advanced algorithms to assist clinicians in accurately locating and sampling breast lesions. Robotic-assisted technologies enable greater dexterity and control during the biopsy procedure, minimizing patient discomfort and procedural complications. The ongoing innovations in these modalities are anticipated to drive growth within the breast biopsy devices market, as healthcare providers seek the most effective means of diagnosing breast cancer.

By Region

The North American region currently dominates the breast biopsy devices market, accounting for a substantial share due to its advanced healthcare infrastructure, high prevalence of breast cancer, and well-established research institutions. The United States, in particular, is at the forefront of technological advancements in medical devices and is home to numerous healthcare facilities that offer a wide range of breast biopsy options. The region is projected to maintain its leadership position, exhibiting a CAGR of approximately 7.5% through the forecast period, driven by continuous innovation and increasing awareness about early cancer detection among the population. The synergy between healthcare providers, patients, and policymakers also fosters a supportive environment for the adoption of advanced biopsy technologies.

Europe is poised to be the second-largest market for breast biopsy devices, attributed to the increasing focus on women's health and rising healthcare expenditures in several countries. Nations such as Germany, France, and the UK are investing heavily in breast cancer screening programs and diagnostic technologies, further enhancing the adoption of breast biopsy devices. As European healthcare systems prioritize preventive care and early diagnosis, the demand for breast biopsy devices is expected to rise steadily. Countries in the Asia Pacific region are also witnessing growing interest in breast biopsy technologies, driven by a rising incidence of breast cancer and improving healthcare infrastructure. The collective growth in these regions reflects the global commitment to combating breast cancer through early detection and effective treatment strategies.

Opportunities

The breast biopsy devices market is poised for significant growth driven by emerging opportunities in various sectors. One of the most promising avenues for expansion lies in the integration of artificial intelligence (AI) and machine learning technologies into diagnostic procedures. By leveraging AI algorithms to analyze imaging results and assist in targeting lesions during biopsy procedures, healthcare professionals can enhance the accuracy and efficiency of breast cancer diagnostics. The ongoing research and development aimed at improving these technologies indicate a strong potential for AI-enhanced biopsy devices, which could revolutionize the standard of care in breast cancer detection and treatment.

Furthermore, the increasing emphasis on patient-centered care presents a unique opportunity for the breast biopsy devices market. As patients become more involved in their healthcare decisions, the demand for personalized and less invasive diagnostic options is rapidly growing. Companies that focus on developing user-friendly devices, improving patient comfort, and promoting quick recovery times are likely to gain a competitive edge. Additionally, the expansion of telemedicine and remote patient monitoring presents an opportunity for healthcare providers to offer comprehensive breast health services, including tele-consultations and follow-up care. By capitalizing on these trends, stakeholders in the breast biopsy devices market can position themselves for sustained growth and success.

Threats

While the breast biopsy devices market presents numerous opportunities, it is not without its challenges. One of the most significant threats is the increasing competition from alternative diagnostic methods, such as liquid biopsies and advanced imaging technologies. These methods may offer less invasive options for cancer detection, which could potentially impact the demand for traditional biopsy procedures. Moreover, as new technologies continue to emerge, there may be a risk of existing devices becoming obsolete, necessitating continuous innovation from manufacturers to maintain their market position. Additionally, stringent regulatory requirements and the need for extensive clinical validation can pose hurdles for new entrants seeking to introduce novel biopsy devices.

Another potential restraining factor is the rising cost of healthcare and the economic pressures faced by patients and healthcare systems. The financial burden associated with breast cancer treatment and diagnostic procedures can deter patients from seeking timely care. This economic strain may also lead healthcare providers to limit their use of advanced biopsy technologies in favor of cost-effective solutions, thereby hindering market growth. Furthermore, disparities in healthcare access across various demographics may result in uneven adoption rates of breast biopsy devices, particularly in lower-income regions. Addressing these challenges will be crucial for stakeholders aiming to thrive in the evolving breast biopsy devices market.

Competitor Outlook

• Hologic, Inc.
• BD (Becton, Dickinson and Company)
• Boston Scientific Corporation
• Medtronic plc
• Siemens Healthineers
• GE Healthcare
• C. R. Bard, Inc.
• Carestream Health, Inc.
• Galil Medical, Inc.
• Intuitive Surgical, Inc.
• Merit Medical Systems, Inc.
• Scanlan International, Inc.
• Sun Medical Technology Research, Inc.
• CooperSurgical, Inc.
• Biopsy Sciences, Inc.

The competitive landscape of the breast biopsy devices market is characterized by a diverse array of players, ranging from large multinational corporations to specialized medical device manufacturers. Leading companies such as Hologic, Inc. and BD (Becton, Dickinson and Company) are at the forefront of innovation, continuously developing advanced biopsy technologies that enhance patient care and diagnostic accuracy. These companies invest heavily in research and development to maintain their competitive edge, focusing on creating minimally invasive, user-friendly devices that address the evolving needs of healthcare providers and patients. In addition, strategic partnerships and collaborations are common in this sector, allowing companies to leverage each other's strengths and expand their market reach.

Other notable players, such as Boston Scientific Corporation and Medtronic plc, are diversifying their product offerings to include a range of breast biopsy devices and related technologies. By combining their expertise in imaging and diagnostic solutions, these companies are well-equipped to address the growing demand for effective breast cancer detection methods. Furthermore, as market dynamics evolve, smaller firms specializing in niche biopsy technologies, such as robotic-assisted and AI-enhanced devices, are gaining traction. These companies aim to capture specific segments of the market by offering innovative solutions that meet the unique needs of healthcare providers and patients alike.

In conclusion, the breast biopsy devices market is poised for growth, driven by a combination of technological advancements, increasing awareness of breast health, and a rise in breast cancer incidences. The competitive landscape is marked by key players committed to innovation and collaboration, ensuring that the market continues to evolve. As stakeholders navigate the challenges and opportunities ahead, aligning their strategies with emerging trends will be essential for achieving sustainable growth and enhancing patient outcomes in breast cancer diagnostics.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 GE Healthcare
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Hologic, Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Medtronic plc
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 C. R. Bard, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Galil Medical, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 CooperSurgical, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Siemens Healthineers
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Biopsy Sciences, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Carestream Health, Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Intuitive Surgical, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Merit Medical Systems, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Scanlan International, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Boston Scientific Corporation
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 BD (Becton, Dickinson and Company)
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Sun Medical Technology Research, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Breast Biopsy Devices Sales Market, By End User
    • 6.1.1 Women's Health Clinics
    • 6.1.2 Cancer Research Institutes
    • 6.1.3 Others
  • 6.2 Breast Biopsy Devices Sales Market, By Application
    • 6.2.1 Hospitals
    • 6.2.2 Diagnostic Centers
    • 6.2.3 Ambulatory Surgical Centers
    • 6.2.4 Others
  • 6.3 Breast Biopsy Devices Sales Market, By Product Type
    • 6.3.1 Core Needle Biopsy Devices
    • 6.3.2 Vacuum-assisted Biopsy Devices
    • 6.3.3 Fine Needle Aspiration Biopsy Devices
    • 6.3.4 MRI-guided Biopsy Devices
    • 6.3.5 Ultrasound-guided Biopsy Devices

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Breast Biopsy Devices Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Breast Biopsy Devices Sales market is categorized based on

By Product Type

• Core Needle Biopsy Devices
• Vacuum-assisted Biopsy Devices
• Fine Needle Aspiration Biopsy Devices
• MRI-guided Biopsy Devices
• Ultrasound-guided Biopsy Devices

By Application

• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers
• Others

By End User

• Women's Health Clinics
• Cancer Research Institutes
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Hologic, Inc.
• BD (Becton, Dickinson and Company)
• Boston Scientific Corporation
• Medtronic plc
• Siemens Healthineers
• GE Healthcare
• C. R. Bard, Inc.
• Carestream Health, Inc.
• Galil Medical, Inc.
• Intuitive Surgical, Inc.
• Merit Medical Systems, Inc.
• Scanlan International, Inc.
• Sun Medical Technology Research, Inc.
• CooperSurgical, Inc.
• Biopsy Sciences, Inc.